Ekso Bionics (NASDAQ:EKSO) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.

Several other equities analysts also recently weighed in on EKSO. Lake Street Capital began coverage on Ekso Bionics in a research report on Monday, June 24th. They set a buy rating and a $2.50 target price on the stock. HC Wainwright reissued a buy rating and set a $10.00 price target on shares of Ekso Bionics in a report on Tuesday, July 30th.

Ekso Bionics Price Performance

NASDAQ EKSO opened at $1.20 on Tuesday. The business’s fifty day moving average price is $1.12 and its 200-day moving average price is $1.21. The stock has a market capitalization of $21.81 million, a price-to-earnings ratio of -1.24 and a beta of 1.45. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.42 and a quick ratio of 1.77. Ekso Bionics has a 1-year low of $0.65 and a 1-year high of $3.13.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Monday, July 29th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $4.95 million for the quarter, compared to analysts’ expectations of $5.34 million. Ekso Bionics had a negative net margin of 68.41% and a negative return on equity of 92.08%. During the same quarter last year, the firm posted ($0.31) earnings per share. On average, equities analysts predict that Ekso Bionics will post -0.42 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC raised its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 596,050 shares of the company’s stock after buying an additional 454,892 shares during the period. Kent Lake Capital LLC owned about 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.